ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01755559
Recruitment Status : Completed
First Posted : December 24, 2012
Last Update Posted : November 30, 2015
Sponsor:
Collaborator:
Centre de Recherche Médicale et Sanitaire (Cermes), Niamey
Information provided by (Responsible Party):
Epicentre

December 19, 2012
December 24, 2012
November 30, 2015
June 2013
November 2014   (Final data collection date for primary outcome measure)
Adequate clinical and parasitological response [ Time Frame: 42 days after treatement start ]
Absence of parasitaemia on day 42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.
Same as current
Complete list of historical versions of study NCT01755559 on ClinicalTrials.gov Archive Site
  • Early treatment failure [ Time Frame: 1 to 3 days after tratment start ]
    • General danger signs or signs of severe malaria on days 1, 2, or 3, in the presence of parasitaemia , or
    • Parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature, or
    • Parasitaemia on day 3 with axillary temperature ≥ 37.5°C, or
    • Parasitaemia on day 3 ≥ 25% count on day 0 irrespective of axillary temperature.
  • Late clinical failure [ Time Frame: from day 4 to day 42 after treatment start ]
    • General danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 42 in patients who did not previously meet any of the criteria of early treatment failure; or
    • Presence of parasitaemia on any day between day 4 and day 42 with axillary temperature ≥ 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure.
  • Late Parasitological Failure [ Time Frame: from day 7 to day 42 after treatment start ]
    - Presence of parasitaemia on any day between day 7 and day 42 with axillary temperature < 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure.
Same as current
Not Provided
Not Provided
 
Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13

Study treatments:

  • Artemether-lumefantrine
  • Artesunate-amodiaquine
  • Dihydroartemisinin-piperaquine

Location:

Maradi, Niger

Principal Objective:

To measure the clinical and parasitological efficacy of the three artemisinin combination therapies over a period of 42 days from the start of treatment and with polymerase chain reaction assay (PCR) adjustment.

Secondary objectives:

  • To determine the blood concentration of the non-artemisinin component of the treatment (lumefantrine, desethylamodiaquine or piperaquine) at day 7
  • To assess the incidence of adverse events during the follow-up period;
  • To measure speed of parasite clearance

Methods:

In vivo non comparative study as for WHO standardised protocol. The study also measure the concentration of the non-artemisinin component.

Target population:

Children under 5 years of age consulting the integrated health centres of Andoumé and Dix-sept portes in Maradi.

Sample size:

221 patients per study treatment; 663 patients in total.

Treatment allocation:

Random.

Outcomes:

  • Early treatment failure,
  • Late clinical failure,
  • Late parasitological failure,
  • Adequate clinical and parasitological response.

Analysis:

  • Cumulative success or failure rate (Kaplan-Meier analysis).
  • Proportions of early treatment failures, late clinical failures, late parasitological failures, and adequate clinical and parasitological response (called also Per-protocol analysis).
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malaria
  • Drug: Artesunate-amodiaquine
    antimalarial ACT
    Other Name: AS-AQ Winthrop® Sanofi Aventis
  • Drug: Dihydroartemisinin-piperaquine
    antimalarial ACT
    Other Name: Euratesim, Sigma-Tau
  • Drug: Artemether-lumefantrine
    antimalarial ACT
    Other Name: Coartem, Novartis
  • Artesunate-amodiaquine
    Efficacy estimates at 95%
    Intervention: Drug: Artesunate-amodiaquine
  • Dihydroartemisinin-piperaquine
    Efficacy estimates at 95%
    Intervention: Drug: Dihydroartemisinin-piperaquine
  • Artemether-lumefantrine
    Efficacy estimates at 95%
    Intervention: Drug: Artemether-lumefantrine
Grandesso F, Guindo O, Woi Messe L, Makarimi R, Traore A, Dama S, Laminou IM, Rigal J, de Smet M, Ouwe Missi Oukem-Boyer O, Doumbo OK, Djimdé A, Etard JF. Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. Malar J. 2018 Jan 25;17(1):52. doi: 10.1186/s12936-018-2200-1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
663
Same as current
November 2014
November 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 6 and 59 months
  • Weight ≥ 5 kg
  • Mono-infection with P. falciparum detected by microscopy
  • Parasitic density between 2,000 and 200,000 asexual forms /µL of blood
  • Axillary temperature ≥ 37.5°C or history of fever during the previous 24 hours
  • Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule (home is within one hour of walk from the outpatient department, no near-term travel plans, etc.)
  • Consent of a parent or guardian who is at least 18 years of age.

Exclusion Criteria:

  • Presence of general danger signs as defined by the WHO,
  • Presence of signs of severe malaria according to the definitions of WHO,
  • Severe anemia (haemoglobin <5 g/dL),
  • Known history of symptomatic cardiac arrhythmias or with clinically relevant bradycardia,
  • Family history of sudden death or of congenital prolongation of corrected QT interval,
  • Use of antiarrhythmics or neuroleptics,
  • Known history of hypersensitivity to any of the study medications,
  • Severe malnutrition (defined as a weight-height ratio of < -3 z-score according to the 2006 WHO reference (20) and / or a mid-upper arm circumference lower than 115 mm and / or the presence of symmetrical oedema of the feet),
  • Presence of a febrile condition due to a disease other than malaria (i.e. measles, acute lower respiratory tract infection, otitis media, tonsillitis, abscess, severe diarrhoea with dehydration, etc.)
  • History of a full treatment course with one of the three study drugs in the past 28 days. The prior incomplete intake of one of the three study drugs or prior intake of antimalarial drugs not being tested in the study does not exclude a patient from participating in this study. However, information on these previous treatments will be carefully recorded.
Sexes Eligible for Study: All
6 Months to 59 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Niger
 
 
NCT01755559
Epicentre/Nig/2012/Palu3ACT
No
Not Provided
Not Provided
Epicentre
Epicentre
Centre de Recherche Médicale et Sanitaire (Cermes), Niamey
Principal Investigator: Francesco Grandesso, MSc Epicentre
Study Chair: Lynda Woi Messe, MD Epicentre
Study Chair: Ibrahim M Laminou, PhD Cermes
Study Chair: Jean-François Etard, PhD Epicentre
Epicentre
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP